We are live on ! Find out more
ALXN

Alexion Pharmaceuticals
ALXN

Delisted

ALXN was delisted on the 20th of July, 2021.

Back to rankings

824 hedge funds and large institutions have $31.3B invested in Alexion Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 204 funds opening new positions, 241 increasing their positions, 284 reducing their positions, and 80 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more funds holding in top 10

Funds holding in top 10: 18 → 46 (+28)

155% more first-time investments, than exits

New positions opened: 204 | Existing positions closed: 80

38% more capital invested

Capital invested by funds: $22.6B → $31.3B (+$8.67B)

28% more call options, than puts

Call options by funds: $559M | Put options by funds: $436M

17% more funds holding

Funds holding: 707 → 824 (+117)

15% less repeat investments, than reductions

Existing positions increased: 241 | Existing positions reduced: 284

Holders
824
Holders Change
+117
Holders Change %
+16.55%
% of All Funds
14.58%
Holding in Top 10
46
Holding in Top 10 Change
+28
Holding in Top 10 Change %
+155.56%
% of All Funds
0.81%
New
204
Increased
241
Reduced
284
Closed
80
Calls
$559M
Puts
$436M
Net Calls
+$123M
Net Calls Change
+$163M

Top Buyers

1
PCM
Pentwater Capital Management
Florida
+$380M
2
FCM
Farallon Capital Management
California
+$289M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$271M
4
HI
HBK Investments
Texas
+$221M
5
Millennium Management
Millennium Management
New York
+$211M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$451M
2
Ameriprise
Ameriprise
Minnesota
-$353M
3
O
OrbiMed
New York
-$259M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$203M
5
AQR Capital Management
AQR Capital Management
Connecticut
-$194M
Name Holding Trade Value Shares
Change 		Change in
Stake
VPIM
651
Vanguard Personalized Indexing Management
California
$226K +$186K +1,448 New
PCS
652
Personal CFO Solutions
New Jersey
$224K +$184K +1,433 New
DBT
653
Dubuque Bank & Trust
Iowa
$221K +$182K +1,413 New
GWA
654
GGM Wealth Advisors
Maryland
$221K +$182K +1,418 New
SW
655
SVB Wealth
Massachusetts
$221K +$182K +1,420 New
XM
656
XTX Markets
New York
$219K +$180K +1,399 New
PBT
657
Pictet Bank & Trust
Bahamas
$219K +$180K +1,400 New
OPA
658
Old Port Advisors
Maine
$218K -$67.7K -527 -27%
BFEC
659
Benjamin F. Edwards & Company
Missouri
$216K -$67.7K -527 -28%
VHAM
660
Van Hulzen Asset Management
California
$216K +$178K +1,385 New
BS
661
Boenning & Scattergood
Pennsylvania
$212K +$175K +1,359 New
MA
662
Mutual Advisors
Nebraska
$211K +$173K +1,348 New
FNBOO
663
First National Bank of Omaha
Nebraska
$208K +$171K +1,330 New
FMLI
664
Fukoku Mutual Life Insurance
Japan
$203K – – –
ER
665
Enlightenment Research
Florida
$203K +$167K +1,300 New
LSA
666
Leonteq Securities AG
Switzerland
$202K +$166K +1,293 New
KMWM
667
Keudell/Morrison Wealth Management
Oregon
$201K +$165K +1,287 New
EI
668
Ellevest Inc
New York
$199K +$120K +934 +277%
TFIPS
669
Towarzystwo Funduszy Inwestycyjnych PZU SA
$180K +$148K +1,155 New
OSAM
670
O'Shaughnessy Asset Management
Connecticut
$172K +$96.8K +753 +218%
SIC
671
Salem Investment Counselors
North Carolina
$168K – – –
SWA
672
Sutton Wealth Advisors
Florida
$167K +$2.31K +18 +2%
MAM
673
Meeder Asset Management
Ohio
$167K -$2.54M -19,734 -95%
SFS
674
Sowell Financial Services
Arkansas
$167K +$16.7K +130 +14%
APA
675
American Portfolios Advisors
New York
$165K -$8.99K -70 -6%
25 26
27
28 29

ALXN Hedge Fund Activity: Q4 2020 in Review

824 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q4 2020, worth a combined $31.3B — up 38% from $22.6B a quarter earlier.

Buyers outnumbered sellers: 204 funds opened new ALXN positions and 80 closed out — a net gain of 124 holders — while 241 added to existing stakes and 284 trimmed.

The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $380M. The largest seller was Fidelity Investments, cutting an estimated $451M.

  • 824 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q4 2020, up from 707 in Q3 2020.
  • Funds reported $31.3B of Alexion Pharmaceuticals stock for Q4 2020, up 38% quarter-over-quarter.
  • 204 funds opened new Alexion Pharmaceuticals positions in Q4 2020 and 80 closed out, a net change of +124 holders.
  • The largest Alexion Pharmaceuticals buyer in Q4 2020 was Pentwater Capital Management, an estimated $380M added.
  • The largest Alexion Pharmaceuticals seller in Q4 2020 was Fidelity Investments, an estimated $451M sold.

Based on aggregated 13F filings for Q4 2020.